{"title":"Comparison of the Tigertriever and Self-expanding Stent Retrievers for Mechanical Thrombectomy of Acute Ischemic Stroke: A Single-center Experience.","authors":"Koichiro Shindo, Kazutaka Uchida, Manabu Shirakawa, Shoichiro Tsuji, Shuntaro Kuwahara, Yoji Kuramoto, Shinichi Yoshimura","doi":"10.2176/jns-nmc.2024-0297","DOIUrl":null,"url":null,"abstract":"<p><p>Stent retrievers, including the novel Tigertriever, are important in mechanical thrombectomy for acute ischemic stroke due to a proximal large-vessel occlusion within the anterior circulation. We aimed to assess the efficacy and safety of the Tigertriever compared to self-expanding stent retrievers like EmboTrap, Solitaire, Trevo, or Tron. Patients treated at a stroke center for intracranial vessel occlusion in the anterior circulation between August 2022 and August 2024 were evaluated. The primary outcome was a modified first-pass effect, defined as a modified thrombolysis in cerebral infarction grade of 2b-3 after the first pass. Secondary outcomes included the first-pass effect, device-related serious adverse events, embolization in new territory, and hemorrhagic complications within 24 hours post-procedure. Data from 104 hemispheres in 103 patients were analyzed (24 in the Tigertriever group and 80 in the stent-retriever group). The Tigertriever group demonstrated a higher modified first-pass effect (70.8% vs. 52.5%; adjusted odds ratio 3.17; 95% confidence interval 1.06-9.47; p = 0.02). Although not statistically significant, vessel dissection (0% vs. 3.8%), subarachnoid hemorrhage (20.8% vs. 32.5%), and symptomatic intracranial hemorrhage (4.2% vs. 12.5%) within 24 hours post-procedure were lower in the Tigertriever group. No significant differences were observed in the first-pass effect or embolization in the new territory between the 2 groups. The Tigertriever might be effective for anterior circulation intracranial vessel occlusion, achieving a higher rate of modified first-pass effect. It might also be associated with minimal serious procedural complications, indicating its safety profile.</p>","PeriodicalId":19225,"journal":{"name":"Neurologia medico-chirurgica","volume":" ","pages":"247-254"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia medico-chirurgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2176/jns-nmc.2024-0297","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Stent retrievers, including the novel Tigertriever, are important in mechanical thrombectomy for acute ischemic stroke due to a proximal large-vessel occlusion within the anterior circulation. We aimed to assess the efficacy and safety of the Tigertriever compared to self-expanding stent retrievers like EmboTrap, Solitaire, Trevo, or Tron. Patients treated at a stroke center for intracranial vessel occlusion in the anterior circulation between August 2022 and August 2024 were evaluated. The primary outcome was a modified first-pass effect, defined as a modified thrombolysis in cerebral infarction grade of 2b-3 after the first pass. Secondary outcomes included the first-pass effect, device-related serious adverse events, embolization in new territory, and hemorrhagic complications within 24 hours post-procedure. Data from 104 hemispheres in 103 patients were analyzed (24 in the Tigertriever group and 80 in the stent-retriever group). The Tigertriever group demonstrated a higher modified first-pass effect (70.8% vs. 52.5%; adjusted odds ratio 3.17; 95% confidence interval 1.06-9.47; p = 0.02). Although not statistically significant, vessel dissection (0% vs. 3.8%), subarachnoid hemorrhage (20.8% vs. 32.5%), and symptomatic intracranial hemorrhage (4.2% vs. 12.5%) within 24 hours post-procedure were lower in the Tigertriever group. No significant differences were observed in the first-pass effect or embolization in the new territory between the 2 groups. The Tigertriever might be effective for anterior circulation intracranial vessel occlusion, achieving a higher rate of modified first-pass effect. It might also be associated with minimal serious procedural complications, indicating its safety profile.
包括新型Tigertriever在内的支架回收器在因前循环近端大血管闭塞引起的急性缺血性中风的机械取栓中发挥着重要作用。我们的目的是评估Tigertriever与EmboTrap、Solitaire、Trevo或Tron等自膨胀支架回收器相比的有效性和安全性。对2022年8月至2024年8月在卒中中心治疗的前循环颅内血管闭塞患者进行评估。主要终点是改良首过效应,定义为首过后脑梗死分级为2b-3的改良溶栓。次要结局包括首次通过效果、器械相关的严重不良事件、新区域栓塞和术后24小时内出血并发症。对103例患者的104个大脑半球的数据进行了分析(Tigertriever组24例,支架取出组80例)。Tigertriever组表现出更高的改良首过效应(70.8% vs. 52.5%;调整优势比3.17;95%置信区间1.06-9.47;P = 0.02)。虽然没有统计学意义,但Tigertriever组术后24小时内血管夹层(0%比3.8%)、蛛网膜下腔出血(20.8%比32.5%)和症状性颅内出血(4.2%比12.5%)较低。两组在首过效果和新区域栓塞方面无显著差异。Tigertriever可能对前循环颅内血管闭塞有效,获得更高的改良首次通过率。它也可能与最小的严重手术并发症有关,表明其安全性。